Eli Lilly, Johnson & Johnson and Pfizer helped drug developer TRexBio close its $59m series A round while Slack backed human resources software provider Oyster at a $475m valuation.
Funding
US-based immunology therapy developer TRexBio completed a $59m series A round yesterday featuring pharmaceutical firms Eli Lilly, Johnson & Johnson and Pfizer. The last two invested through Johnson & Johnson Innovation – JJDC and Pfizer Ventures respectively, and the round included Alexandria Venture Investments, the venture capital arm of life science real estate investment trust Alexandria Real Estate Equities, as well as SV Health.
US-headquartered recruitment software provider Oyster secured $50m yesterday in a series B round that included…
